Market Overview

Global Breast Cancer Liquid Biopsy Market Forecasts to 2022 - Rising Emphasis on Personalized Medicine


Global Breast Cancer Liquid Biopsy Market Forecasts to 2022 - Rising Emphasis on Personalized Medicine

PR Newswire

DUBLIN, Aug 24, 2018 /PRNewswire/ --

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

The "Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison, Competitive Landscape - Global Forecasts to 2022" report has been added to's offering.

The global breast cancer liquid biopsy market is projected to reach USD 411.1 million by 2022 from USD 145.4 million in 2017, at a CAGR of 23.1%.

Factors such as increasing prevalence of breast cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the growth of the breast cancer liquid biopsy market.

The report analyzes the breast cancer liquid biopsy market by circulating biomarker, end user, and region. On the basis of circulating biomarkers, the breast cancer liquid biopsy market is segmented into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The cfDNA segment is the largest and fastest-growing segment in the circulating biomarkers market during the forecast period. The growing research on cfDNA owing to its occurrence in other body fluids along with the blood of cancer patients and the real-time results obtained by the analysis of cfDNA are the major factors contributing to the growth of cfDNA in the breast cancer liquid biopsy market.

Based on end user, the breast cancer liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, and other end users (research institutes, public health laboratories, pathology laboratories, and small molecular laboratories). In 2017, the reference laboratories segment accounted for the largest share of the breast cancer liquid biopsy market. The large share is attributed to the availability of advanced genetic testing equipment leading to an increased volume of liquid biopsy test samples outsourced to reference laboratories.

Key Topics Covered:

1 Liquid Biopsy: Market at A Glance

1.1 Introduction
1.2 Issues Addressed By Liquid Biopsy & Biomarkers Detected
1.3 Milestones in Liquid Biopsy

2 Liquid Biopsy: Circulating Biomarkers

2.1 Liquid Biopsy Market for Circulating Tumor DNA (CTDNA)
2.2 CTDNA Approaches: Applications and Limitations
2.3 Methods for CTC Isolation

3 Liquid Biopsy: Market Overview

3.1 Introduction
3.1.1 Drivers High Burden of Cancer Increasing Preference for Noninvasive Procedures Initiatives Undertaken By Governments and Global Health Organizations Technological Advancements Rising Emphasis on Personalized Medicine Availability of Funding for Liquid Biopsy R&D
3.1.2 Restraints Low Sensitivity and Specificity
3.1.3 Opportunities Growing Interest in Liquid Biopsy
3.1.4 Challenges Unclear Regulatory and Reimbursement Scenario

4 Major Investments & Initiatives

4.1 Government Funding & Initiatives
4.2 Industry Investments and Initiatives

5 Breast Cancer Liquid Biopsy Market

5.1 Breast Cancer Liquid Biopsy Market: Global Scenario
5.2 Potential of Liquid Biopsy and CTC in Breast Cancer Diagnosis

6 Liquid Biopsy Market: Competitive Landscape

6.1 Introduction
6.2 Key Strategies
6.2.1 Acquisitions and Mergers
6.2.2 Product Launches
6.2.3 Agreements, Partnerships, and Collaborations
6.3 Liquid Biopsy Market: Competitive Technology Portfolio

7 Appendix

Companies Mentioned

  • Roche Diagnostics
  • Illumina, Inc.
  • Bio-Rad Laboratories
  • Myriad Genetics
  • Menarini Silicon Biosystems
  • Cynvenio Biosystems, Inc.
  • Genomic Health, Inc.
  • Thermo Fisher Scientific Inc.
  • Fluxion Biosciences, Inc.
  • Biodesix, Inc.
  • Guardant Health, Inc.
  • Isogen Life Science B.V.

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


Cision View original content with multimedia:

SOURCE Research and Markets

View Comments and Join the Discussion!